Publications

Found 148 results
[ Type(Desc)] Year
Journal Article
LR Polstein, P Perez-Pinera, DD Kocak, CM Vockley, P Bledsoe, L Song, A Safi, GE Crawford, TE Reddy, and CA Gersbach. "Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators." Genome Res 25, no. 8 (2015): 1158-1169.
IC McDowell, A Barrera, AM D'Ippolito, CM Vockley, LK Hong, SM Leichter, LC Bartelt, WH Majoros, L Song, A Safi et al. "Glucocorticoid receptor recruits to enhancers and drives activation by motif-directed binding." Genome Res 28, no. 9 (2018): 1272-1284.
JE Phillips, CA Gersbach, AM Wojtowicz, and AJ García. "Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation." Journal of Cell Science 119, no. Pt 3 (2006): 581-591.
MS Bhakta, IM Henry, DG Ousterout, KT Das, SH Lockwood, JF Meckler, MC Wallen, A Zykovich, Y Yu, H Leo et al. "Highly active zinc-finger nucleases by extended modular assembly." Genome Research 23, no. 3 (2013): 530-538.
PI Thakore, AM D'Ippolito, L Song, A Safi, NK Shivakumar, AM Kabadi, TE Reddy, GE Crawford, and CA Gersbach. "Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements." Nat Methods 12, no. 12 (2015): 1143-1149.
DW Dumbauld, TT Lee, A Singh, J Scrimgeour, CA Gersbach, EA Zamir, J Fu, CS Chen, JE Curtis, SW Craig et al. "How vinculin regulates force transmission." Proceedings of the National Academy of Sciences of the United States of America 110, no. 24 (2013): 9788-9793.
S Pregizer, A Barski, CA Gersbach, AJ García, and B Frenkel. "Identification of novel Runx2 targets in osteoblasts: cell type-specific BMP-dependent regulation of Tram2." Journal of Cellular Biochemistry 102, no. 6 (2007): 1458-1471.
V Gough, and CA Gersbach. "Immunity to Cas9 as an Obstacle to Persistent Genome Editing." Molecular Therapy 28, no. 6 (2020): 1389-1391.
CA Gersbach, RE Guldberg, and AJ García. "In vitro and in vivo osteoblastic differentiation of BMP-2- and Runx2-engineered skeletal myoblasts." Journal of Cellular Biochemistry 100, no. 5 (2007): 1324-1336.
JB Kwon, AR Ettyreddy, A Vankara, JD Bohning, G Devlin, SD Hauschka, A Asokan, and CA Gersbach. "In Vivo Gene Editing of Muscle Stem Cells with Adeno-Associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy." Molecular Therapy Methods & Clinical Development 19 (2020): 320-329.
CE Nelson, CH Hakim, DG Ousterout, PI Thakore, EA Moreb, RM Castellano Rivera, S Madhavan, X Pan, FA Ran, WX Yan et al. "In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy." Science 351, no. 6271 (2016): 403-407.
DJ Landau, ED Brooks, P Perez-Pinera, H Amarasekara, A Mefferd, S Li, A Bird, CA Gersbach, and DD Koeberl. "In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA." Molecular Therapy : the Journal of the American Society of Gene Therapy 24, no. 4 (2016): 697-706.
D Manandhar, L Song, A Kabadi, JB Kwon, LE Edsall, M Ehrlich, K Tsumagari, CA Gersbach, GE Crawford, and R Gordân. "Incomplete MyoD-induced transdifferentiation is associated with chromatin remodeling deficiencies." Nucleic Acids Res 45, no. 20 (2017): 11684-11699.
DD Kocak, EA Josephs, V Bhandarkar, SS Adkar, JB Kwon, and CA Gersbach. "Increasing the specificity of CRISPR systems with engineered RNA secondary structures." Nature Biotechnology 37, no. 6 (2019): 657-666.
CA Gersbach, JM Le Doux, RE Guldberg, and AJ García. "Inducible regulation of Runx2-stimulated osteogenesis." Gene Therapy 13, no. 11 (2006): 873-882.
JB Kwon, and CA Gersbach. "Jumping at the chance for precise DNA integration." Nature Biotechnology 37, no. 9 (2019): 1004-1006.
BO Diekman, PI Thakore, SK O'Connor, VP Willard, JM Brunger, N Christoforou, KW Leong, CA Gersbach, and F Guilak. "Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells." Tissue Engineering. Part A 21, no. 7-8 (2015): 1261-1274.
LR Polstein, and CA Gersbach. "A light-inducible CRISPR-Cas9 system for control of endogenous gene activation." Nature Chemical Biology 11, no. 3 (2015): 198-200.
LR Polstein, and CA Gersbach. "Light-inducible gene regulation with engineered zinc finger proteins." Methods in Molecular Biology (Clifton, N.J.) 1148 (2014): 89-107.
LR Polstein, and CA Gersbach. "Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors." Journal of the American Chemical Society 134, no. 40 (2012): 16480-16483.
CE Nelson, Y Wu, MP Gemberling, ML Oliver, MA Waller, JD Bohning, JN Robinson-Hamm, K Bulaklak, RM Castellano Rivera, JH Collier et al. "Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy." Nat Med 25, no. 3 (2019): 427-432.
BE Housden, M Muhar, M Gemberling, CA Gersbach, DYR Stainier, G Seydoux, SE Mohr, J Zuber, and N Perrimon. "Loss-of-function genetic tools for animal models: cross-species and cross-platform differences." Nature Reviews. Genetics 18, no. 1 (2017): 24-40.
JB Black, P Perez-Pinera, and CA Gersbach. "Mammalian Synthetic Biology: Engineering Biological Systems." Annual Review of Biomedical Engineering 19 (2017): 249-277.
JB Black,, S Dube, A Barrera, TS Klann, GA Rice, SS Adkar, SH Soderling, TE Reddy, and CA Gersbach. "Master Regulators and Cofactors of Human Neuronal Cell Fate Specification Identified by CRISPR Gene Activation Screens." Cell Reports 33, no. 9 (2020).
DG Ousterout, AM Kabadi, PI Thakore, WH Majoros, TE Reddy, and CA Gersbach. "Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy." Nature Communications 6 (2015): 6244-.

Pages